# A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma

> **NCT07691762** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 690 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** SHR-8068 + Adebrelimab + Bevacizumab
- **DRUG:** SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo
- **DRUG:** SHR-8068 Placebo + Adebrelimab + Bevacizumab

## Key facts

- **NCT ID:** NCT07691762
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2031-04
- **Final completion:** 2031-04
- **Target enrollment:** 690 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691762, "A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07691762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*